CANTIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CANTIL (CANTIL).
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
| Metabolism | Primarily metabolized by ester hydrolysis; excreted unchanged in bile and urine. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 1.2-1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 60-70% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-10 minutes. |
| Duration of Action | Oral: 4-6 hours; intravenous: 2-4 hours. Duration may be prolonged in patients with hepatic or renal impairment. |
| Molecular Weight | 352.47 |
| Action Class | Fungal ergosterol synthesis inhibitor |
| Brand Substitutes | Czson Cream, Clocip Cream 15 gm for Skin Infections, Imidil Cream, Clotrex Cream, Colocaz 1% Cream |
50 mg orally three times daily, may increase to 100 mg three times daily if needed
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: 50 mg twice daily; eGFR 15-29 mL/min: 50 mg once daily; eGFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended |
| Pediatric use | Safety and efficacy not established in pediatric patients; use not recommended |
| Geriatric use | Start at 25 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity and renal impairment risk |
| 1st trimester | Contraindicated due to risk of fetal anticholinergic effects; insufficient human data from adequate studies. |
| 2nd trimester | Contraindicated; limited data suggest potential fetal harm from anticholinergic activity. |
| 3rd trimester | Contraindicated; possible neonatal adverse effects including ileus and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for CANTIL (CANTIL).
| Placental transfer | Likely crosses placenta due to molecular weight <500 Da, but specific studies lacking. |
| Breastfeeding | Excreted in breast milk in small amounts; potential for anticholinergic effects in infant such as constipation, dry mouth, or tachycardia. Caution advised; monitor infant for adverse effects. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
GlaucomaObstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy)Gastrointestinal obstructive disease (e.g., pyloroduodenal stenosis)Paralytic ileusMyasthenia gravisUnstable cardiovascular status in acute hemorrhage
| Precautions | Heat prostration in hot environments due to decreased sweating; glaucoma; urinary retention; hyperthyroidism; coronary artery disease; congestive heart failure; cardiac arrhythmias; hiatal hernia; impaired renal or hepatic function; prostatic hypertrophy; obstructive uropathy. |
| Food/Dietary | Avoid high-fat meals as they may delay absorption. No specific food interactions; maintain adequate fluid intake to prevent constipation. |
Loading safety data…
| L3 - Moderately Safe |
| Teratogenic Risk | CANTIL (mepenzolate bromide) is an anticholinergic quaternary ammonium compound. Limited human data; no evidence of teratogenicity in animal studies. In first trimester, theoretical risk of minor malformations due to anticholinergic effects; avoid unless clearly needed. Second and third trimesters: may cause fetal tachycardia, decreased GI motility, and potentially contribute to meconium ileus or neonatal anticholinergic syndrome if used near term. Weigh risk versus benefit. |
| Fetal Monitoring | Maternal: Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Fetal: Fetal heart rate monitoring during labor if used near term; assess for signs of fetal tachycardia or reduced variability. Neonatal: Observe for anticholinergic syndrome (lethargy, irritability, feeding difficulties) after delivery if used chronically or in high doses. |
| Fertility Effects | Anticholinergic agents can potentially affect fertility by altering cervical mucus consistency and impairing sperm motility due to changes in seminal fluid. In females, may suppress lactation or affect ovulatory function via central mechanisms, but no specific data for CANTIL. Use caution in patients attempting conception. |
| Clinical Pearls | CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic used for functional gastrointestinal disorders. Avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. May exacerbate GERD by reducing lower esophageal sphincter tone. Onset is rapid; duration 4-6 hours. Use with caution in elderly due to risk of anticholinergic side effects. |
| Patient Advice | Take CANTIL 30-60 minutes before meals and at bedtime. · Avoid driving or operating machinery if you experience drowsiness or blurred vision. · Report severe constipation, difficulty urinating, or eye pain immediately. · Do not take with antacids; separate by at least 2 hours. · Limit alcohol consumption as it may increase sedation. |